PodParley PodParley
PodParley
Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter? episode artwork

EPISODE · Apr 30, 2025 · 36 MIN

Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?

from Talking Euretina · host Whipsmart Media

Dr. Sarah Mrejen (France), Associate Professor Salomon Cohen (France), and Associate Professor Dinah Zur (Israel) explore how neovascular AMD phenotype may influence imaging choices, patient dialogue, and treatment plans. From proactive vs. conservative strategies to new anti-VEGF agents and PCV diagnosis, this expert-led discussion offers key insights into personalising care in retinal disease.

Episode metadata supplied by the publisher feed · Published Apr 30, 2025

Embed this episode

NOW PLAYING

Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?

0:00 36:41

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Talking Euretina?

This episode is 36 minutes long.

When was this Talking Euretina episode published?

This episode was published on April 30, 2025.

Can I download this Talking Euretina episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!